Nigeria’s struggle with opioid abuse will not be won through half measures. The current quasi-ban on Tramadol – restricting but not eliminating imports, leaves the door open for abuse, diversion, and public harm. The only policy that matches the scale of the problem is a total ban on Tramadol importation, with legitimate medical supply met exclusively through onshore production under direct regulatory oversight.
Partial restrictions have consistently failed. When a legal import channel exists, it becomes a pipeline for the illicit market. Criminal networks exploit quota systems, falsify documentation, and divert shipments meant for hospitals and pharmacies to street dealers. The result is predictable: high-strength Tramadol circulates widely among young people, commercial drivers, and students. The consequences are measurable in rising rates of addiction, mental health disorders, road accidents, and preventable deaths. A quasi-ban reduces volume, but it does not break the supply chain that enables abuse.
A total ban removes ambiguity. Enforcement becomes straightforward: any Tramadol above approved medical doses found outside NAFDAC-monitored local production is illegal. That clarity matters for law enforcement, port authorities, and the judiciary. It closes the regulatory gray area that traffickers currently exploit to argue “legal” origin for illicit consignments. Without an import channel, there is no legal cover for large-scale diversion.
Regional experience proves the point. Egypt, Ghana, and Tanzania imposed strict bans or near-bans on high-strength Tramadol formulations and recorded measurable declines in abuse, overdose cases, and seizures. Nigeria cannot afford to remain the weak link in West Africa’s drug safety chain. If neighbouring countries restrict supply while Nigeria keeps a legal import window open, the region will continue to channel drugs through our ports and borders.
This argument gained urgency at the recently concluded Pharma West Africa 2026 Conference in Lagos. Stakeholders warned that West Africa’s 70-95% dependence on imported medicines remains a major threat to health security. The consensus was clear: the problem is no longer a lack of resources, but the failure to build a coordinated system that links healthcare delivery, financing, and local production.
As Maisha Meds International Chief Growth Officer – Olamide Okulaja put it; we face a “disconnected ecosystem” where service delivery, capital flow, and production operate in silos.
Tramadol illustrates this disconnect perfectly. Import channels create demand signals for foreign suppliers, not for Nigerian plants. A total ban would redirect that signal onshore, giving local manufacturers the volume and predictability they need to invest in capacity, quality control, and traceability.
Onshore production under direct NAFDAC oversight is the alternative that protects patients without enabling abuse. Nigeria now has over twenty newly registered local manufacturers operating WHO-compliant facilities, backed by more than two billion dollars in investment. These plants can meet legitimate medical demand for Tramadol where it is clinically necessary, under conditions that allow real-time inspection, batch testing, and traceability.
Producing locally makes diversion harder to hide. It is easier for regulators to audit a facility in Ogun State, conduct unannounced inspections, and enforce Good Manufacturing Practice than to chase falsified consignments across multiple ports of entry. NAFDAC’s return to port operations between 2018 and 2022 demonstrated that physical presence and direct oversight reduce counterfeit inflows. The same principle applies to Tramadol: produce where you can see, test, and enforce.
Public health and industrial policy reinforce each other here. A total import ban channels demand toward domestic capacity, improving economies of scale and lowering unit costs for legitimate patients. It accelerates Nigeria’s shift from a 70-30 import-local ratio toward self-reliance, without compromising access for patients who genuinely need the drug for pain management. More importantly, it removes the industrial-scale supply that fuels addiction and crime.
The argument against a total ban – that it will create shortages for patients, is addressed by regulated onshore production and post-marketing surveillance. NAFDAC already has the mandate and technical capacity to approve, inspect, and monitor local manufacturers. What it lacks is a policy environment that removes the competing illegal supply route. As conference speakers noted, implementation of existing policies remains inadequate, and digital innovation must be matched with political will and investment.
Pharma West Africa 2026 attracted over 250 exhibitors and 4,500 visitors from across the globe, signalling strong international interest in Nigeria’s market. That interest will translate into real investment only if Nigeria demonstrates it can secure its supply chain and enforce standards. A total Tramadol ban would send that signal.
Nigeria cannot afford to reset the clock on pharmaceutical regulation now. A total ban on Tramadol imports, paired with strict oversight of onshore production, closes the door on abuse while preserving access for legitimate medical use. Anything less will keep the country exposed to a public health and security threat that has already cost too many lives. The infrastructure exists, the manufacturers exist, the data exists, and the policy levers exist. What remains is the decision to connect them.
English